Gabriel Leung has been Vice Chairman and a director of Novocure since 2011. Mr. Leung retired as Executive Vice President of OSI Pharmaceuticals, Inc. and as the President of OSI’s Oncology and Diabetes Business following OSI’s acquisition by Astellas Pharma Inc. in 2010. Mr. Leung was responsible for the launch of Tarceva (erlotinib) at OSI Pharmaceuticals, guiding the product to the most successful launch in U.S. oncology history with global sales exceeding $1.2 billion in 2009. Prior to his tenure at OSI, Mr. Leung served as Group Vice President of the Global Prescription Business at Pharmacia Corporation from 1999 to 2003, leading Pharmacia’s oncology franchise with business and medical affairs operations in over 80 countries. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company. Mr. Leung currently serves on the board of Pernix Therapeutics Holdings, Inc. and previously served on the boards of Albany Molecular Research Inc. and Delcath Systems, Inc. Mr. Leung is a pharmacist and trained at the University of Texas at Austin where he earned his B.S. degree with High Honors. Mr. Leung earned his M.S. in Pharmacy from the University of Wisconsin-Madison, with a concentration in pharmaceutical marketing.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.